A prodrug of dextroamphetamine has been approved by the FDA for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is the d-amphetamine covalently bound to l-lysine. It is marketed by Shire US Inc as Vyvanse.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content